ENCORE SEOUL

  • Home
  • Contact us
ȸ���α��� ID PW Forgot ID/PW Register Automatically Log me on

New antiplatelet drugs and novel oral anticoagulant during percutaneous coronary intervention

NOA have significantly improved the outcomes of patients with NVAfib, but have no current role in ACS patients.
NOA are likely to present a better safety profile than VKA in patiens undergoing stent implantation, and RCTs are currently addressing this hypothesis.

Prasugrel and ticagrelor are the standard of care for high risk ACS patients with no increased risk of bleeding.
Cangrelor could be a useful treatment for reducing intraprocedural complication pending approval and drug cost.

DETAIL VIEW
Best Focus

coronary

  • lecture
  • case
read more

vascular

  • lecture
  • case
read more